← Leaderboards
Raphael A. Nemenoff
University Of Colorado Denver
$15,000,654
Attributed
$16,204,975
Total exposure
14
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $954.3K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$16,204,975 · 14
By mechanism
R01$9,694,209 · 6
P50$3,774,633 · 6
P01$2,339,937 · 1
R21$396,196 · 1
Top collaborators
- Joshua M Thurman5 shared
- Mary Cm Weiser-Evans2 shared
Most similar at University Of Colorado Denver
Same institution · by research overlap
- Paul A Bunn$21,859,370
- York E Miller$6,348,289
- Rajesh Agarwal$27,337,251
- Wilbur A Franklin$9,400,239
- James V Degregori$21,700,379
Others in their field
Top investigators on “Lung Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$351,628,955
- Richard K. Wilson · Washington University$202,666,376
- Walter John Curran · Thomas Jefferson University$94,374,902
- Jan C Buckner · Mayo Clinic Coll Of Medicine, Rochester$61,110,512
- William J. Blot · Vanderbilt University$59,429,890
- Charles A Coltman · Southwest Oncology Group$54,703,213
Research focus
Lung NeoplasmsPathway InteractionsMediatingCellsMalignant Neoplasm Of LungLungNeoplastic CellMolecularGrowthProductionNon-Small-Cell Lung CarcinomaProteinsResponseIn VitroTumorGene ExpressionCancer CellMalignant NeoplasmsFundingNeoplasm MetastasisReceptorProstaglandins IPlayLung Tumorigenesis
Grant awards (68)
Colorado HNC SPORE Career Enhancement Program$96,390
P50 · FY2025 · CA · contact PI
Colorado HNC SPORE Career Enhancement Program$90,746
P50 · FY2024 · CA · contact PI
Effects of Complement on the Tumor Microenvironment in Lung Cancer$394,879
R01 · FY2023 · CA · contact PI
Colorado HNC SPORE Career Enhancement Program$91,104
P50 · FY2023 · CA · contact PI
Effects of Complement on the Tumor Microenvironment in Lung Cancer$394,879
R01 · FY2022 · CA · contact PI
The Lung Tumor Microenvironment: Role of Resident Pulmonary Vascular Progenitor Cells in Cancer Progression and Metastasis$178,107
R21 · FY2022 · CA
Colorado HNC SPORE Career Enhancement Program$91,103
P50 · FY2022 · CA · contact PI
Effects of Complement on the Tumor Microenvironment in Lung Cancer$402,938
R01 · FY2021 · CA · contact PI
The Lung Tumor Microenvironment: Role of Resident Pulmonary Vascular Progenitor Cells in Cancer Progression and Metastasis$218,089
R21 · FY2021 · CA
Effects of Complement on the Tumor Microenvironment in Lung Cancer$402,938
R01 · FY2020 · CA · contact PI
Effects of Complement on the Tumor Microenvironment in Lung Cancer$416,813
R01 · FY2019 · CA · contact PI
Prostacyclin and Peroxisome Proliferator-Activated Receptor-Gamma in Lung Cancer$290,197
P50 · FY2018 · CA · contact PI
Prostacyclin and Peroxisome Proliferator-Activated Receptor-Gamma in Lung Cancer$6,134
P50 · FY2018 · CA · contact PI
Eicosanoids in Lung Cancer: Progression and Metastasis$322,663
R01 · FY2017 · CA · contact PI
Prostacyclin and Peroxisome Proliferator-Activated Receptor-Gamma in Lung Cancer$295,040
P50 · FY2017 · CA · contact PI
Eicosanoids in Lung Cancer: Progression and Metastasis$322,663
R01 · FY2016 · CA · contact PI
Prostacyclin and Peroxisome Proliferator-Activated Receptor-Gamma in Lung Cancer$273,099
P50 · FY2016 · CA · contact PI
Eicosanoids in Lung Cancer: Progression and Metastasis$321,625
R01 · FY2015 · CA · contact PI
Peroxisome Proliferator-Activated Receptor (gamma) in Lung Cancer$297,398
R01 · FY2015 · CA · contact PI
Prostacyclin and Peroxisome Proliferator-Activated Receptor-Gamma in Lung Cancer$276,434
P50 · FY2015 · CA · contact PI
Eicosanoids in Lung Cancer: Progression and Metastasis$310,970
R01 · FY2014 · CA · contact PI
Peroxisome Proliferator-Activated Receptor (gamma) in Lung Cancer$288,476
R01 · FY2014 · CA · contact PI
Prostacyclin and Peroxisome Proliferator-Activated Receptor-Gamma in Lung Cancer$274,905
P50 · FY2014 · CA · contact PI
Eicosanoids in Lung Cancer: Progression and Metastasis$319,550
R01 · FY2013 · CA · contact PI
Peroxisome Proliferator-Activated Receptor (gamma) in Lung Cancer$279,554
R01 · FY2013 · CA · contact PI
Prostacyclin and Peroxisome Proliferator- Activated Receptor Gamma in Lung Cancer$123,332
P50 · FY2013 · CA · contact PI
Peroxisome Proliferator-Activated Receptor (gamma) in Lung Cancer$297,398
R01 · FY2012 · CA · contact PI
Prostacyclin and Peroxisome Proliferator- Activated Receptor Gamma in Lung Cancer$268,719
P50 · FY2012 · CA · contact PI
Peroxisome Proliferator-Activated Receptor (gamma) in Lung Cancer$297,398
R01 · FY2011 · CA · contact PI
Prostacyclin and Peroxisome Proliferator- Activated Receptor Gamma in Lung Cancer$266,444
P50 · FY2011 · CA · contact PI
Role of cPLA2 in Lung Cancer: Microenvironment vs Tumor Cells$280,917
R01 · FY2010 · CA · contact PI
Prostacyclin and Peroxisome Proliferator- Activated Receptor Gamma in Lung Cancer$279,316
P50 · FY2010 · CA · contact PI
Prostacyclin and Peroxisome Proliferator- Activated Receptor Gamma in Lung Cancer$297,556
P50 · FY2009 · CA · contact PI
Role of cPLA2 in Lung Cancer: Microenvironment vs Tumor Cells$281,835
R01 · FY2009 · CA · contact PI
VASCULAR SMOOTH MUSCLE REMODELING IN RESPONSE TO ARGININE VASOPRESSIN$389,533
P01 · FY2008 · DK · contact PI
Peroxisome Proliferator Activated Receptors in Lung Cancer$288,845
R01 · FY2008 · CA · contact PI
Prostacyclin and Peroxisome Proliferator- Activated Receptor Gamma in Lung Cancer$193,606
P50 · FY2008 · CA · contact PI
VASCULAR SMOOTH MUSCLE REMODELING IN RESPONSE TO ARGININE VASOPRESSIN$385,538
P01 · FY2007 · DK · contact PI
Peroxisome Proliferator Activated Receptors in Lung Cancer$288,845
R01 · FY2007 · CA · contact PI
Cytosolic Phospholipase in Transformed Cells$260,078
R01 · FY2007 · CA · contact PI
VASCULAR SMOOTH MUSCLE REMODELING--ARGININE VASOPRESSIN$386,657
P01 · FY2006 · DK · contact PI
Preroxisome Proliferator-Activated Receptors in lung Cancer$297,472
R01 · FY2006 · CA · contact PI
Cytosolic Phospholipase in Transformed Cells$267,846
R01 · FY2006 · CA · contact PI
VASCULAR SMOOTH MUSCLE REMODELING--ARGININE VASOPRESSIN$375,394
P01 · FY2005 · DK
Preroxisome Proliferator-Activated Receptors in lung Cancer$304,630
R01 · FY2005 · CA
Cytosolic Phospholipase in Transformed Cells$274,292
R01 · FY2005 · CA
VASCULAR SMOOTH MUSCLE REMODELING--ARGININE VASOPRESSIN$364,459
P01 · FY2004 · DK
Peroxisome Proliferator Activated Receptors in Cancer$304,630
R01 · FY2004 · CA
Cytosolic Phospholipase in Transformed Cells$274,292
R01 · FY2004 · CA
Cytosolic Phospholipase in Transformed Cells$272,694
R01 · FY2003 · CA
Prostacyclin Synthase in the Development of Lung Cancer$0
P50 · FY2003 · CA
CYTOSOLIC PHOSPHOLIPASE A2 TRANSFORMED CELLS$226,896
R01 · FY2002 · DK
SIGNALING PATHWAYS REGULATED BY MECHANICAL STRAIN IN VSM$188,750
R01 · FY2002 · HL
ROLE OF EICOSANOIDS IN LUNG CANCER GROWTH$61,783
P50 · FY2002 · CA
CYTOSOLIC PHOSPHOLIPASE A2 TRANSFORMED CELLS$220,418
R01 · FY2001 · DK
SIGNALING PATHWAYS REGULATED BY MECHANICAL STRAIN IN VSM$188,750
R01 · FY2001 · HL
ROLE OF EICOSANOIDS IN LUNG CANCER GROWTH$61,783
P50 · FY2001 · CA
ROLE OF EICOSANOIDS IN LUNG CANCER GROWTH$61,783
P50 · FY2001 · CA
ROLE OF EICOSANOIDS IN LUNG CANCER GROWTH$61,783
P50 · FY2001 · CA
VASOPRESSIN SIGNALLING PATHWAYS IN VASCULAR SMOOTH MUSCLE CELLS$0
P01 · FY2001 · DK
VASOPRESSIN SIGNALLING PATHWAYS IN VASCULAR SMOOTH MUSCLE CELLS$0
P01 · FY2001 · DK
VASOPRESSIN SIGNALLING PATHWAYS IN VASCULAR SMOOTH MUSCLE CELLS$219,178
P01 · FY2000 · DK
VASOPRESSIN SIGNALLING PATHWAYS IN VASCULAR SMOOTH MUSCLE CELLS$219,178
P01 · FY2000 · DK
CYTOSOLIC PHOSPHOLIPASE A2 TRANSFORMED CELLS$214,127
R01 · FY2000 · DK
SIGNALING PATHWAYS REGULATED BY MECHANICAL STRAIN IN VSM$188,750
R01 · FY2000 · HL
ROLE OF EICOSANOIDS IN LUNG CANCER GROWTH$156,688
P50 · FY2000 · CA
ROLE OF EICOSANOIDS IN LUNG CANCER GROWTH$156,688
P50 · FY2000 · CA
VASOPRESSIN SIGNALLING PATHWAYS IN VASCULAR SMOOTH MUSCLE CELLS$0
P01 · FY2000 · DK